MEDULLOBLASTOMA IN CHILDREN:
MOLECULAR SUBGROUPS & TREATMENT
The most common malignant brain tumour in children is now a molecularly stratified disease — where WNT-activated tumours are nearly always curable and Group 3 tumours define the frontier of paediatric neuro-oncology research.
analyticsAt a Glance
- check_circleFour molecular subgroups — WNT, SHH, Group 3, Group 4 — define biology, prognosis, and treatment intensity
- check_circleWNT-activated medulloblastoma has >95% long-term survival — the most curable high-risk CNS tumour
- check_circleCraniospinal irradiation is standard for non-infant patients but carries significant long-term developmental risks
- check_circleCancerFax connects families to specialist paediatric neuro-oncology centres and clinical trial access
What Is Medulloblastoma and How Is It Diagnosed?
Medulloblastoma is a WHO grade 4 embryonal tumour arising from the cerebellum — the posterior fossa region of the brain responsible for coordination and balance. It is the most common malignant brain tumour in children, typically presenting between ages 3 and 16 with headache, vomiting, and progressive ataxia caused by cerebellar dysfunction and hydrocephalus.
“Medulloblastoma is no longer one disease — it is four biologically distinct tumours that happen to share the same location and the same name.”
Diagnosis: Imaging and Surgery
Contrast-enhanced MRI brain and spine is essential at diagnosis to stage disease (local vs metastatic). Surgical resection provides tissue for histological typing AND molecular subgroup classification — both are now required for treatment planning.
Why Molecular Subgroup Matters
Molecular subgroup — determined by DNA methylation profiling, immunohistochemistry, or gene expression — predicts outcome more accurately than histology or age alone, and increasingly guides decisions about treatment intensity: de-escalation for WNT, intensification for Group 3.
The Four Molecular Subgroups of Medulloblastoma
Each subgroup has distinct biology, age distribution, clinical features, and prognosis — the most consequential molecular classification in paediatric neuro-oncology.
| Subgroup | Frequency | Key Biology | 5-Year OS | Clinical Notes |
|---|---|---|---|---|
| WNT-activated | ~10% | CTNNB1 mutation; nuclear β-catenin; monosomy 6 | >95% | Most curable; de-escalation trials actively reducing RT dose to limit toxicity |
| SHH-activated | ~30% | PTCH1/SMO/SUFU/GLI2 mutations; TP53 status critical | 40–80% | TP53-mutant SHH has poor prognosis; vismodegib being studied; infant SHH managed without RT |
| Group 3 | ~25% | MYC amplification in ~20%; SMARCA4 mutations | 40–60% | Highest metastatic rate; worst prognosis; platinum-based intensification and trials critical |
| Group 4 | ~35% | Most common; SNCAIP duplication, CDK6 amplification; isochromosome 17q | 70–85% | Intermediate prognosis; reduced RT dose trials ongoing for standard-risk subgroup |
Standard Treatment Sequence for Medulloblastoma
Treatment follows a defined sequence of surgery, radiation, and chemotherapy — with intensity adjusted by molecular subgroup, age, and risk stratification (standard-risk vs high-risk).
- 1
Maximal Safe Surgical Resection
Surgery aims for gross total or near-total resection — extent of resection is a key component of risk stratification. Posterior fossa syndrome (cerebellar mutism) is the most feared complication and occurs in 20–25% of posterior fossa surgeries — typically resolves over weeks to months.
- 2
Post-operative MRI and CSF Cytology
Contrast-enhanced MRI brain and spine within 24–72 hours post-surgery assesses residual disease. CSF cytology via lumbar puncture (performed ≥14 days post-surgery) completes staging.
- 3
Risk Stratification
Patients are classified as standard-risk (no metastases, no residual tumour >1.5 cm², non-infant, non-WNT/SHH TP53-mutant) or high-risk (metastatic, large residual, or unfavourable molecular subgroup) — determining radiation dose.
- 4
Craniospinal Irradiation (CSI)
23.4 Gy craniospinal + 54–55.8 Gy posterior fossa boost (standard-risk) or 36 Gy craniospinal + 54–55.8 Gy boost (high-risk). CSI is not used in infants under 3 years due to devastating neurodevelopmental effects.
- 5
Adjuvant Chemotherapy
Platinum-based chemotherapy (cisplatin, vincristine, cyclophosphamide/lomustine) is given during and after CSI for high-risk patients. The SJMB03 and PNET5 protocols define the most widely adopted regimens.
Survival by Molecular Subgroup
Molecular subgroup defines the prognosis range for medulloblastoma more accurately than any other clinical variable — a near-100% vs 40% survival spread across subgroups.
5-Year Overall Survival by Molecular Subgroup
Source: Cavalli et al, Cancer Cell 2017; Taylor et al, Acta Neuropathol 2012 — approximate ranges across published series
- WNT-activated>95%
- Group 470–85%
- SHH-activated (TP53-wt)60–80%
- Group 340–60%
- SHH-activated (TP53-mutant)~40%
Treatment Outcomes vs Long-Term Effects
Medulloblastoma survival rates have improved dramatically since the 1980s — but at a cost. Long-term survivors face a significant burden of treatment-related late effects, particularly from craniospinal irradiation.
Treatment Successes
- WNT tumours: near-universal cureThe WNT subgroup has transformed from a high-risk diagnosis to a near-universally curable one — with active de-escalation trials now asking whether RT dose can be safely reduced.
- Improved Group 3 survival with intensificationHigh-dose chemotherapy with autologous stem cell rescue (HDC-ASCT) protocols have improved Group 3 outcomes from historically <40% to 50–60% 5-year survival at expert centres.
- Proton therapy reducing neurocognitive damageProton craniospinal irradiation spares the cochlea, hippocampus, and developing brain better than photon RT — significantly reducing IQ decline and hearing loss in long-term survivors.
Long-Term Late Effects
- Neurocognitive declineCraniospinal irradiation causes IQ decline averaging 2–4 points per year in the years following treatment — more severe in younger children and those requiring higher RT doses.
- Endocrine deficienciesGrowth hormone deficiency occurs in >90% of medulloblastoma survivors treated with CSI. Hypothyroidism, adrenal insufficiency, and delayed puberty are common — requiring lifelong endocrine monitoring.
- Hearing lossCisplatin-related ototoxicity causes significant hearing loss in 20–50% of treated children — with proton RT and amifostine both showing some protective benefit.
Frequently Asked Questions
Common questions from families of children diagnosed with medulloblastoma.
About Diagnosis and Treatment
How important is it to test the molecular subgroup?
Extremely important — and increasingly required. Without molecular subgroup classification, risk stratification is incomplete and treatment decisions (particularly de-escalation for WNT or intensification for Group 3) cannot be made correctly. DNA methylation profiling at a reference neuropathology centre is the gold standard. CancerFax can assist with routing tumour tissue for molecular profiling.
Can medulloblastoma be treated without radiation in young children?
In infants and children under 3 years, craniospinal irradiation is generally avoided due to its devastating effect on the developing brain. Chemotherapy-only protocols (such as Head Start) are used with curative intent in this age group — with radiation reserved for relapse or persistent disease. The outcomes are subgroup-dependent, with SHH-activated tumours doing best in chemotherapy-only approaches.
What is the role of proton therapy in medulloblastoma?
Proton craniospinal irradiation is preferred over photon CSI at centres where it is available — it delivers the same tumour dose with significantly lower dose to the cochlea, hippocampus, heart, and lungs, reducing hearing loss, neurocognitive decline, and second malignancy risk. CancerFax can identify proton therapy centres with paediatric medulloblastoma programmes, including SPHIC in Shanghai.
What clinical trials are open for medulloblastoma?
Major ongoing trials include SIOPE PNET5 (de-escalation for standard-risk and WNT tumours), SJMB12 (risk-stratified therapy at St Jude), and multiple SHH-inhibitor trials (vismodegib, sonidegib) for SHH-activated tumours. CancerFax can assist families in identifying open trials and eligibility, including international access pathways.
More from the Brain Tumour Treatment Resource Library
Explore related guides on paediatric and adult brain tumour treatment, radiosurgery, and surgery techniques.
- ↑ Brain Tumour Treatment — Complete Guide
- 5-ALA Fluorescence-Guided Brain Tumour Surgery
- Intraoperative MRI for Brain Tumour Surgery
- Proton and Carbon Ion Therapy for Brain Tumours at SPHIC Shanghai
- Oligodendroglioma and 1p/19q Co-Deletion: The Most Curable High-Grade Brain Tumour
- Meningioma Treatment: Surgery, Gamma Knife, and Observation
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Get Expert Guidance on Medulloblastoma Treatment Access
CancerFax reviews molecular subgroup reports, risk stratification, and treatment history — and connects families with specialist paediatric neuro-oncology centres experienced in molecular-subgroup-stratified treatment and clinical trial enrolment.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified paediatric neuro-oncologist before making treatment decisions.